Efficacy and safety of the breast biopsy marker (UltraClip) insertion in patients with breast cancer who undergo neoadjuvant chemotherapy

Efficacy and safety of the breast biopsy marker (UltraClip) insertion in patients with breast cancer who undergo neoadjuvant chemotherapy - Efficacy and safety of UltraClip in cases of neoadjuvant chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027267

Enrollment

100

Registered

2017-05-08

Start date

2016-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

The intervention is only once at the time of USMMT.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients are diagnosed the breast cancer by physical examination and image. The patient was provided in a document about the participation in this study from a subject

Exclusion criteria

Exclusion criteria: The patients have a low probability of neoadjvant chemotherapy. The patients is likely to the benign tumor. The patients are judged that the medical attendant was inadequate for this trial.

Design outcomes

Primary

Measure	Time frame
False-negative rate in the cCR group	—

Secondary

Measure	Time frame
Stump negative rate Safety of UltraClip The marker insertion rate in the operation group and non cCR group The marker insertion rate in residual tumor in the Non pCR group	—

Countries

Japan

Contacts

Public ContactAyumi Kataoka

Aichi Cancer Center Hospital Department of Breast oncology

a-kataoka@aichi-cc.jp052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026